Clinical trials: Biliary Tract Cancer, open to volunteers
Pancreas Cancer, Cholangiocarcinoma
The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer
In this study, the investigators aim to demonstration of relationship between triceps skinfold thickness and overall survival of pancreatic cancer, cholangiocarcinoma and GB cancer.
- Conditions
- Pancreas Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT03637569
- Testing
- Measurement of triceps skinfold thickness
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Samsung Medical Center
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
Cholangiocarcinoma
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure…
- Trial name
- NCT05874414
- Testing
- GNS561 + Trametinib
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- Genfit
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive tumor…
- Trial name
- NCT07107750
- Testing
- Emavusertib, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Clinical trial phase: Phase 2 Intervention model: Control group Group allocation: Randomized controlled trial Research perspective: Prospective study Participating centers: Multicenter study Definition of the intervention period…
- Conditions
- Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma
- Trial name
- Dulastin (NCT06135896)
- Testing
- Tripegfilgrastim
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- National Cancer Center, Korea
Biliary Track Cancer
Histotripsy in Biliary Tract Cancer
The purpose of this pilot study is to examine the safety and feasibility of histotripsy in two cohorts of 12 patients each with Biliary Track Cancer (BTC), with a plan to expand to a larger multi-center study if both safety and…
- Trial name
- NCT07853690
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Primary Sclerosing Cholangitis, PSC
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
- Conditions
- Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
- Trial name
- NCT04753996
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gastric Cancer, Gastroesophageal Junction Cancer
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06219941
- Testing
- AZD0901, 5-Fluorouracil, Leucovorin
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
Biliary tract carcinoma (BTC), including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, ranks sixth in incidence among gastrointestinal malignancies and tenth in cancer-related mortality…
- Conditions
- Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma
- Trial name
- NCT07176962
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Yingbin Liu, MD, PhD, FACS
Pancreatic Cancer, Periampullary Cancer
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing…
- Conditions
- Pancreatic Cancer, Periampullary Cancer, Duodenal Cancer, Cholangiocarcinoma
- Trial name
- NBCA-MS (NCT07155525)
- Testing
- Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2), Standard(duct-to-mucosa) Pancreaticojejunostomy
- Where
- Egypt
- Volunteers
- 194 people
- Sponsor
- Minia University
Biliary Tract Cancer (BTC)
Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer
The trial will assess the efficacy, safety, and tolerability of daraxonrasib monotherapy in Asian patients with RAS-mutated advanced biliary tract cancer in second-line treatment.
- Trial name
- NCT07908550
- Testing
- Daraxonrasib
- Where
- Taiwan
- Volunteers
- 55 people
- Sponsor
- National Health Research Institutes, Taiwan
Biliary Tract Cancer, Disitamab Vedotin
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
This trial is a single-arm exploratory phase II clinical study initiated by the investigator. Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with…
- Conditions
- Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors
- Trial name
- NCT07159217
- Testing
- Disitamab Vedotin, Lenvatinib, Pembrolizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over…
- Trial name
- Beacon-BTC (NCT07265674)
- Testing
- Nanvuranlat, Physician's Best Choice
- Where
- 18 sites in United States
- Volunteers
- 480 people
- Sponsor
- J-Pharma Co., Ltd.
Biliary Tract Cancer
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC).
- Trial name
- NCT07450976
- Testing
- SHR-A1904 for Injection
- Where
- 2 sites in China
- Volunteers
- 151 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cholangiocarcinoma Non-resectable, Gall Bladder Cancer
Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction
The goal of this clinical randomized controlled trial is to perform primary percutaneous stenting (PPS) in patients with malignant hilar biliary obstruction (MHBO).
- Conditions
- Cholangiocarcinoma Non-resectable, Gall Bladder Cancer, Liver Metastasis, Malignant Hilar Stricture
- Trial name
- TESLA RCT (NCT06671418)
- Testing
- Primary percutaneous stenting (PPS), Endoscopic biliary drainage
- Where
- Netherlands
- Volunteers
- 148 people
- Sponsor
- Erasmus Medical Center
Breast Cancer, Biliary Tract Carcinoma
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
- Conditions
- Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT05123482
- Testing
- AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib)
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 460 people
- Sponsor
- AstraZeneca